MERCK & CO INC shareholders Q3 2023

MERCK & CO INC's ticker is MRK and the CUSIP is 58933Y105. A total of 3,124 filers reported holding MERCK & CO INC in Q3 2023. The put-call ratio across all filers is 0.78 and the average weighting 0.6%.

MERCK & CO INC shareholders Q3 2023
NameSharesValueWeighting ↓
SL ADVISORS, LLC 201,200$2,713,5003.65%
A. D. Beadell Investment Counsel, Inc. 33,940$3,4943.65%
Commonwealth Retirement Investments LLC 61,055$6,285,6123.63%
Founders Capital Management 45,748$4,709,7263.60%
M&R CAPITAL MANAGEMENT INC 126,976$13,072,1403.58%
MUFG Securities EMEA plc 465,000$47,871,7503.53%
COMPASS CAPITAL MANAGEMENT, INC 435,707$44,856,0363.52%
Stillwater Capital Advisors, LLC 186,758$19,226,7783.50%
CADINHA & CO LLC 152,041$15,652,6153.46%
BOURGEON CAPITAL MANAGEMENT LLC 143,011$14,722,9973.46%
FOUNDATION RESOURCE MANAGEMENT INC 199,823$20,571,7783.42%
Private Wealth Partners, LLC 346,791$35,702,1063.41%
THORNBURG INVESTMENT MANAGEMENT INC 2,016,111$207,5593.41%
PRIVATE ASSET MANAGEMENT INC 140,380$14,452,3323.39%
Magnetar Financial LLC 1,286,768$132,472,7663.38%
S&CO INC 396,887$40,8593.36%
Hi-Line Capital Management, LLC 87,205$9,041,3863.33%
Quilter Plc 845,955$844,093,8993.33%
Brick & Kyle, Associates 60,872$6,2673.32%
Genus Capital Management Inc. 204,434$21,046,4803.31%
About MERCK & CO INC

Merck & Co Inc. is a leading pharmaceutical company that has been in operation for over a century. The company is known for its innovative research and development of drugs that have helped to improve the health and well-being of millions of people around the world.

Merck & Co Inc. has a strong pipeline of drugs that are in various stages of development. The company's focus on research and development has helped it to stay ahead of its competitors in the pharmaceutical industry. Merck & Co Inc. has a number of drugs that are currently in clinical trials, and the company is optimistic about the potential of these drugs to treat a range of diseases.

One of the key strengths of Merck & Co Inc. is its commitment to sustainability. The company has set ambitious goals to reduce its environmental impact and to promote social responsibility. Merck & Co Inc. has been recognized for its efforts in sustainability, and the company is committed to continuing to make progress in this area.

Merck & Co Inc. has a strong financial position, with a solid balance sheet and a history of consistent earnings growth. The company's strong financial position has allowed it to invest in research and development, and to pursue strategic acquisitions that have helped to expand its product portfolio.

Overall, Merck & Co Inc. is a well-respected pharmaceutical company that has a strong track record of innovation and success. With a focus on sustainability and a commitment to research and development, the company is well-positioned for continued growth and success in the years ahead.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists MERCK & CO INC's shareholders in Q3 2023. To view MERCK & CO INC's shareholder history, click here.